Pulsethera’s first FDA submission:
Device/ROS combination for skin MRSA decolonization and treatment
A third of Americans are colonized with Staphylococcus aureus and more than 3 million people are colonized with MRSA.
In 2020, an estimated 279,300 MRSA infections occurred among hospitalized patients in the US (In-hospital mortality of approximately 30%).
Universal decolonization has been shown significantly more effective at reducing bloodstream MRSA infections than either targeted decolonization or screening / isolation.
Pulsethera’s device anticipated to be adopted in decolonization standard of care to minimize post-operative infections.
Modified device for healthcare personal to prevent MRSA infection
Upon demonstrating safety, a home device will be available for MRSA